Shopping Cart

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2025

SKU
GDHC139PIDR
READ MORE
USD 10,995
Single User License
USD 10,995
Site License
USD 21,990
Corporate User License
USD 32,985

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2025

Summary

Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the w

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2025

Summary

Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC, and are likely to change the treatment paradigm for these patients.

This report highlights the significant unmet need for expansion in the HER2- breast cancer marker across the eight major markets; it also discusses the associated commercial opportunities for new market entrants to gain a foothold in the market. GlobalData anticipates the HER2- breast cancer market to almost double, from $5.43B to $10.58B, over the forecast period of 2015-2025. The key drivers will be the incorporation of CDK4/6 inhibitors into the first-line metastatic setting and the rise of new targeted therapies and immunotherapies.

Highlights

Key Questions Answered

In HER2-/HR+ breast cancer, the recent launch of CDK4/6 inhibitors in the US market has changed the paradigm of treatment in metastatic setting in these patients. How will new late-stage drugs will be positioned in comparison to the CDK 4/6 inhibitor Ibrance (palbociclib)? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Chemotherapy agents used in breast cancer are mostly well-established generics used in combination or as monotherapy. How will the advent of new therapies change the drug treatment landscape for HER2-negative breast cancer?

Several new late-stage agents target specific patients population. How will these agents will compete against chemotherapies in terms of efficacy and market size?

Key Findings

In 2015, the value of the HER2- breast cancer market in the 8MM was estimated to be $5.43B. This is forecast to grow to $10.58B by the end of the forecast period, with China the main driver of growth.

The largest driver will be the incorporation of premium priced CDK4/6 inhibitors into the first line setting. Pfizer's Ibrance and Novartis' ribociclib are expected to each reach blockbuster status by the end of the forecast period.

However, patent expiries of several blockbuster drugs and pricing difficulties are expected to limit growth in the HER2- breast cancer market over the forecast period.

Large market opportunities remain for the development of novel therapies in patients who acquire resistance to endocrine therapy.

Scope

Overview of HER2- breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines and disease management.

Annualized HER2- breast cancer therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2015 and forecast for seven years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HER2- breast cancer therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of middle- to late-stage pipeline drugs.

Analysis of the current and future market competition in the global HER2- breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global HER2- breast cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- breast cancer therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global HER2- breast cancer therapeutics market from 2015-2025.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 11

1.1 List of Tables 18

1.2 List of Figures 25

2 Introduction 30

2.1 Catalyst 30

2.2 Related Reports 31

2.3 Upcoming Related Reports 31

3 Disease Overview 32

3.1 Etiology and Pathophysiology 32

3.1.1 Etiology 32

3.1.2 Pathophysiology 33

3.1.3 Basic Breast Anatomy 35

3.2 Disease Classification/Staging Systems 36

3.3 Symptoms 38

3.4 Prognosis 38

3.5 Quality of Life 39

4 Epidemiology 42

4.1 Disease Background 42

4.2 Risk Factors and Comorbidities 43

4.3 Global Trends 46

4.3.1 US 46

4.3.2 5EU 47

4.3.3 Japan 47

4.3.4 China (Urban) 48

4.3.5 Prevalence and Survival 49

4.4 Forecast Methodology 52

4.4.1 Sources Used Tables 53

4.4.2 Forecast Assumptions and Methods 65

4.4.3 Sources Not Used 85

4.5 Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015-2025) 86

4.5.1 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer 86

4.5.2 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status 88

4.6 Epidemiological Forecast for Invasive Breast Cancer (2015-2025) 90

4.6.1 Diagnosed Incident Cases of Invasive Breast Cancer 90

4.6.2 Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer 92

4.6.3 Age-Standardized Diagnosed Incidence of Invasive Breast Cancer 94

4.6.4 Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer 95

4.6.5 Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis 97

4.6.6 Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status 99

4.6.7 Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis 101

4.6.8 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression 105

4.6.9 Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression 108

4.7 Discussion 110

4.7.1 Epidemiological Forecast Insight 110

4.7.2 Limitations of the Analysis 112

4.7.3 Strengths of the Analysis 114

5 Disease Management 116

5.1 Diagnosis and Treatment Overview 116

5.1.1 Screening and Diagnosis 116

5.1.2 Treatment Overview of Loco-Regional Breast Cancer 117

5.1.3 Neoadjuvant and Adjuvant Treatment Regimen 121

5.1.4 Treatment of Metastatic HR+ Disease 127

5.1.5 Treatment of Metastatic TNBC 128

5.1.6 Treatment Guidelines and Leading Prescribed Drugs 130

5.2 US 131

5.2.1 Diagnosis 131

5.2.2 Clinical Practice 132

5.3 France 135

5.3.1 Diagnosis 135

5.3.2 Clinical Practice 136

5.4 Germany 138

5.4.1 Diagnosis 138

5.4.2 Clinical Practice 139

5.5 Italy 141

5.5.1 Diagnosis 141

5.5.2 Clinical Practice 142

5.6 Spain 144

5.6.1 Diagnosis 144

5.6.2 Clinical Practice 145

5.7 UK 147

5.7.1 Diagnosis 147

5.7.2 Clinical Practice 148

5.8 Japan 150

5.8.1 Diagnosis 150

5.8.2 Clinical Practice 151

5.9 China 153

5.9.1 Diagnosis 153

5.9.2 Clinical Practice 154

6 Competitive Assessment 157

6.1 Overview 157

6.2 Product Profiles (Branded Therapies) 158

6.2.1 Ibrance (palbociclib) 158

6.2.2 Abraxane (nab-paclitaxel) 170

6.2.3 Afinitor (everolimus) 176

6.2.4 Avastin (bevacizumab) 183

6.2.5 Halaven (eribulin mesylate) 189

6.2.6 Ixempra (ixabepilone) 196

6.2.7 Faslodex (fulvestrant) 202

6.2.8 Doxil/Caelyx (pegylated liposomal doxorubicin) 212

6.3 Product Profiles (Hormonal Agents) 216

6.3.1 Tamoxifen 216

6.3.2 Aromatase Inhibitors 219

7 Unmet Needs and Opportunities 223

7.1 Overview 223

7.1.1 Defined Treatment Plan for BRCA+ Patients and the Prevention of Prophylactic Surgeries 225

7.1.2 Targeted Treatment Options for Triple Negative Breast Cancer Patients 227

7.1.3 Treatment of Brain Metastasis 230

7.1.4 For HR+ Patients, Reduced Resistance to Hormonal Agents 232

7.1.5 Improved Convenience of Administration of Hormonal Agents 234

8 Pipeline Assessment 237

8.1 Overview 237

8.2 CDK4/6 inhibitors 241

8.2.1 Abemaciclib (LY2835219) 242

8.2.2 Ribociclib (LEE011) 250

8.3 Poly ADP-Ribose Polymerase Inhibitors 258

8.3.1 Lynparza (olaparib) 259

8.3.2 Talazoparib (BMN 673) 267

8.3.3 Veliparib (ABT-888) 272

8.3.4 Niraparib (MK4827) 277

8.4 Phosphoinositide 3 Kinase Inhibitors 285

8.4.1 Buparlisib (BKM- 120) 286

8.4.2 Alpelisib (BYL-719) 293

8.4.3 Taselisib (GDC-0032) 300

8.5 PD-1/PD-L1 Checkpoint Inhibitors 306

8.5.1 Tecentriq (atezolizumab) 308

8.5.2 Keytruda (pembrolizumab) 314

8.6 Histone Deacetylase Inhibitors 320

8.6.1 Entinostat 320

8.6.2 Epidaza (chidamide) 326

8.7 Antibody Drug Conjugates 333

8.7.1 Sacituzimab govitecan (IMMU-132) 333

8.7.2 Glembatumumab vedotin (CDX-011) 339

8.8 Others 346

8.8.1 Xtandi (enzalutamide) 346

8.9 Promising Drugs in Early Stage Clinical Development 354

8.9.1 Seviteronel 355

8.9.2 Ipatasertib 356

8.9.3 Vanctitumab 357

8.9.4 IDO Checkpoint Inhibitors 359

9 Current and Future Players 362

9.1 Overview 362

9.2 Trends in Corporate Strategy 366

9.3 Company Profiles 369

9.3.1 Pfizer 369

9.3.2 Novartis 373

9.3.3 Roche 375

9.3.4 AstraZeneca 378

10 Market Outlook 382

10.1 Global Markets 382

10.1.1 Forecast 382

10.1.2 Drivers and Barriers-Global Issues 388

10.2 US 391

10.2.1 Forecast 391

10.2.2 Key Events 395

10.2.3 Drivers and Barriers 397

10.3 5EU 399

10.3.1 Forecast 399

10.3.2 Key Events 403

10.3.3 Drivers and Barriers 405

10.4 Japan 408

10.4.1 Forecast 408

10.4.2 Key Events 411

10.4.3 Drivers and Barriers 412

10.5 China 414

10.5.1 Forecast 414

10.5.2 Key Events 417

10.5.3 Drivers and Barriers 418

11 Appendix 422

11.1 Bibliography 422

11.2 Abbreviations 470

11.3 Methodology 479

11.4 Forecasting Methodology 479

11.4.1 Diagnosed Patients with HER2- Breast Cancer 479

11.4.2 Percent Drug-Treated Patients 480

11.4.3 Drugs Included in Each Therapeutic Class 480

11.4.4 Launch and Patent Expiration Dates 482

11.4.5 General Pricing Assumptions 483

11.4.6 Average Body Weight and Surface Area Across the 8MM 485

11.4.7 General Forecast Assumptions 485

11.4.8 Individual Drug Assumptions 485

11.4.9 TS-1 Assumptions 492

11.4.10 Generic Erosion 492

11.4.11 Pricing of Pipeline Agents 492

11.5 Primary Research-Key Opinion Leaderss Interviewed for This Report 503

11.6 Primary Research-High-Prescribers Surveyed for this Report 505

11.7 About the Authors 506

11.7.1 Author 506

11.7.2 Epidemiologist 506

11.7.3 Therapy Director 507

11.7.4 Epidemiology Director 508

11.7.5 Global Director of Therapy Analysis and Epidemiology 508

11.8 About GlobalData 509

11.9 Disclaimer 509


List Of Figure

1.2 List of Figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 36

Figure 2: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages ?18 Years, Women, Cases per 100,000 Population, 2005?2014 46

Figure 3: Case Flow Map 52

Figure 4: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ?18 Years, Selected Years, 2015-2025 88

Figure 5: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ?18 Years, 2015 90

Figure 6: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, Selected Years, 2015-2025 92

Figure 7: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, 2015 94

Figure 8: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, 2015 95

Figure 9: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ?18 Years, Select Years, 2015-2025 97

Figure 10: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, 2015 99

Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages ?18 Years, 2015 101

Figure 12: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, 2015 102

Figure 13: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ?18 Years, 2015 103

Figure 14: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ?18 Years, 2015 104

Figure 15: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages ?18 Years, 2015 105

Figure 16: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, 2015 106

Figure 17: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages ?18 Years, 2015 107

Figure 18: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages ?18 Years, 2015 108

Figure 19: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, 2015 109

Figure 20: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages ?18 Years, 2015 110

Figure 21: Overview of Non-Invasive and Invasive Breast Cancer Treatment 117

Figure 22: Neoadjuvant/Adjuvant Settings Treatment Paradigm in HER2- Breast Cancer 124

Figure 23: Key Late-Stage Key Clinical Trials of Ibrance 162

Figure 24: Key Late-Stage Key Clinical Trials of Abraxane 173

Figure 25: Key Late-Stage Key Clinical Trials of Afinitor 179

Figure 26: Key Late-Stage Clinical Trials of Avastin 186

Figure 27: Key Late-Stage Clinical Trials of Halaven 192

Figure 28: Key Late-Stage Clinical Trials of Ixempra 198

Figure 29: Key Late-Stage Clinical Trials of Faslodex 206

Figure 30: Late-Stage Clinical Trials of Drugs in HR+ Breast Cancer 239

Figure 31: Late-Stage Clinical Trials of Drugs in TNBC 240

Figure 32: Key Late-Stage Clinical Trials of Abemaciclib 244

Figure 33: Clinical and Commercial Positioning of Abemaciclib 248

Figure 34: Key Late-Stage Clinical Trials of Ribociclib 251

Figure 35: Clinical and Commercial Positioning of Ribociclib 256

Figure 36: Key Late-Stage Clinical Trials of Lynparza 260

Figure 37: Clinical and Commercial Positioning of Lynparza 265

Figure 38: Key Late-Stage Clinical Trials of Talazoparib 267

Figure 39: Clinical and Commercial Positioning of Talazoparib 271

Figure 40: Key Late-Stage Clinical Trials of Veliparib 273

Figure 41: Clinical and Commercial Positioning of Veliparib 276

Figure 42: Key Late-Stage Clinical Trials of Niraparib 279

Figure 43: Clinical and Commercial Positioning of Niraparib 283

Figure 44: Key Late-Stage Clinical Trials of Buparlisib 289

Figure 45: Clinical and Commercial Positioning of Buparlisib 292

Figure 46: Key Late-Stage Clinical Trials of Alpelisib 295

Figure 47: Clinical and Commercial Positioning of Alpelisib 298

Figure 48: Key Late-Stage Clinical Trials of Taselisib 302

Figure 49: Clinical and Commercial Positioning of Taselisib 305

Figure 50: Key Late-Stage Clinical Trials of Tecentriq 310

Figure 51: Clinical and Commercial Positioning of Tecentriq 313

Figure 52: Key Late-Stage Clinical Trials of Keytruda 315

Figure 53: Clinical and Commercial Positioning of Keytruda 319

Figure 54: Key Late-Stage Clinical Trials of Entinostat 322

Figure 55: Clinical and Commercial Positioning of Entinostat 325

Figure 56: Key Late-Stage Clinical Trials of Epidaza 329

Figure 57: Clinical and Commercial Positioning of Epidaza 331

Figure 58: Key Late-Stage Clinical Trials of Sacituzumab Govitecan 335

Figure 59: Clinical and Commercial Positioning of sacituzimab govitecan 338

Figure 60: Key Late-Stage Clinical Trials of Glembatumumab Vedotin 341

Figure 61: Clinical and Commercial Positioning of Glembatumumab Vedotin 344

Figure 62: Key Late-Stage Clinical Trials of Xtandi 349

Figure 63: Clinical and Commercial Positioning of Xtandi 352

Figure 64: Global Sales of Branded Products for HER2- Breast Cancer by Company, 2015 and 2025 365

Figure 65: Company Portfolio Gap Analysis in HER2- Breast Cancer, 2015-2025 366

Figure 66: Pfizer SWOT Analysis in HER2- Metastatic Breast Cancer, 2016 372

Figure 67: Novartis SWOT Analysis in HER2- Metastatic Breast Cancer, 2016 375

Figure 68: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016 378

Figure 69: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016 381

Figure 70: Global Sales ($M) for HER2- Breast Cancer by Region, 2015-2025 386

Figure 71: Global Sales for HER2- Breast Cancer by Drug, 2015-2025 387

Figure 72: Sales for HER2-/HR+ Breast Cancer in the US by Drug, 2015-2025 393

Figure 73: Sales for TNBC Breast Cancer in the US by Drug, 2015-2025 394

Figure 74: Sales for HER2-/HR+ Breast Cancer in the 5EU by Drug, 2015-2025 401

Figure 75: Sales for TNBC Breast Cancer in the 5EU by Drug, 2015-2025 402

Figure 76: Sales for HER2-/HR+ Breast Cancer in Japan by Drug, 2015-2025 409

Figure 77: Sales for TNBC Breast Cancer in Japan by Drug, 2015-2025 410

Figure 78: Sales for HER2-/HR+ Breast Cancer in China by Drug, 2015-2025 415

Figure 79: Sales for TNBC Breast Cancer in China by Drug, 2015-2025 416


List Of Table

1.1 List of Tables

Table 1: Molecular Subtypes of Breast Cancer 33

Table 2: AJCC Stage Definitions for Breast Cancer 37

Table 3: Prognosis for Breast Cancer 38

Table 4: Risk Factors and Comorbidities for Breast Cancer 44

Table 5: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%) 49

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer 53

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status 54

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer 55

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status 56

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer 57

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis 58

Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis 59

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis 60

Table 14: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status 61

Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis 62

Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression 63

Table 17: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer 85

Table 18: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 87

Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 89

Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 91

Table 21: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N (Row %), 2015 93

Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages ?18 Years, N, Select Years, 2015-2025 96

Table 23: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages ?18 Years, N, 2015 98

Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages ?18 Years, N, 2015 100

Table 25: Treatment Guidelines for HER2- Breast Cancer 130

Table 26: Most Prescribed Regimens for HER2- Breast Cancer by Drug Class in the Global Markets, 2015 131

Table 27: Country Profile-US 132

Table 28: Country Profile-France 136

Table 29: Country Profile-Germany 139

Table 30: Country Profile-Italy 142

Table 31: Country Profile-Spain 145

Table 32: Country Profile-UK 148

Table 33: Country Profile-Japan 151

Table 34: Country Profile-China 154

Table 35: Product Profile-Ibrance 160

Table 36: Summary of the Results of the PALOMA-2 Trial 164

Table 37: Summary of the Results of the PALOMA-3 Trial 165

Table 38: Safety profile of Ibrance + letrozole 167

Table 39: Safety Profile of Ibrance in Combination with Faslodex 168

Table 40: Ibrance SWOT Analysis, 2016 169

Table 41: Product Profile-Abraxane 172

Table 42: Efficacy of Abraxane 174

Table 43: Safety Profile of Abraxane 175

Table 44: Abraxane SWOT Analysis, 2016 176

Table 45: Product Profile-Afinitor (everolimus) 178

Table 46: Efficacy of Afinitor in Second-Line HER2-/HR+ Advanced Breast Cancer 181

Table 47: Safety Profile of Afinitor 182

Table 48: Afinitor SWOT Analysis, 2016 182

Table 49: Product Profile-Avastin 184

Table 50: Efficacy of Avastin in First Line Metastatic Breast Cancer 187

Table 51: Safety of Avastin in First-Line Metastatic Breast Cancer 188

Table 52: Avastin SWOT Analysis, 2016 189

Table 53: Product Profile-Halaven 191

Table 54: Efficacy of Halaven 194

Table 55: Safety Profile of Halaven 195

Table 56: Halaven SWOT Analysis, 2016 196

Table 57: Product Profile-Ixempra 197

Table 58: Efficacy of Ixempra Monotherapy 199

Table 59: Efficacy of Ixempra in Combination with Xeloda 200

Table 60: Safety Profile of Ixempra 201

Table 61: Ixempra SWOT Analysis, 2016 202

Table 62: Product Profile-Faslodex 205

Table 63: Efficacy of Faslodex in the First Line 207

Table 64: Efficacy of Faslodex Monotherapy in the Second Line 208

Table 65: Efficacy of Faslodex in the First Line 208

Table 66: Safety of Faslodex in the First Line 209

Table 67: Safety of Faslodex in the Second Line 210

Table 68: Faslodex SWOT Analysis, 2016 211

Table 69: Product Profile-Doxil 213

Table 70: Doxil SWOT Analysis, 2016 216

Table 71: Product Profile-Nolvadex/Soltamox 218

Table 72: AI Approvals in the 8MM 221

Table 73: Unmet Need and Opportunity in HER2- Breast Cancer 225

Table 74: Product Profile-Abemaciclib (LY2835219) 244

Table 75: Efficacy of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients (MONARCH 1 NCT02102490) 246

Table 76: Safety of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients 247

Table 77: Abemaciclib SWOT Analysis, 2016 249

Table 78: Product Profile-Ribociclib 251

Table 79: Efficacy of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021) 254

Table 80: Most Common AEs of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021) 255

Table 81: Ribociclib SWOT Analysis, 2015 257

Table 82: Product Profile-Lynparza 261

Table 83: Summary of the Results of the ICEBERG 1 Phase II Trial (NCT00494234) 263

Table 84: Summary of the Most Commonly Reported AEs, Occurring in at Least 20% of Patients With Advanced Ovarian Cancers Treated with Lynparza Monotherapy 264

Table 85: Lynparza SWOT Analysis, 2016 266

Table 86: Product Profile-Talazoparib 268

Table 87: Summary of the Most Commonly Reported AEs in Patients Treated with Talazoparib Monotherapy 270

Table 88: Talazoparib SWOT Analysis, 2016 272

Table 89: Product Profile-Veliparib 274

Table 90: Veliparib SWOT Analysis, 2016 277

Table 91: Product Profile-Niraparib 279

Table 92: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Niraparib 282

Table 93: Niraparib SWOT Analysis 2016 284

Table 94: Product Profile-Buparlisib (BKM-120) 287

Table 95: Summary of the Results of the Trial of Buparlisib + Faslodex vs. Faslodex 290

Table 96: Summary of AEs From the Trial of Buparlisib + Faslodex vs. Faslodex 291

Table 97: Buparlisib SWOT Analysis 293

Table 98: Product Profile-Alpelisib (BYL- 719) 294

Table 99: Summary of the Results of the Alpelisib Trial 296

Table 100: Summary of AEs from the Trial of Alpelisib 297

Table 101: Alpelisib SWOT Analysis 299

Table 102: Product Profile-Taselisib (GDC-0032) 300

Table 103: Summary of the Results of the Taselisib Trial 303

Table 104: Summary of the Safety of Taselisib 304

Table 105: Taselisib SWOT Analysis 306

Table 106: Product Profile-Tecentriq 309

Table 107: Summary of the Results of the Phase Ib Trial of Tecentriq in Combination with Abraxane in Patients with mTNBC (Genetech, NCT01633970) 311

Table 108: Summary of AEs from the Phase Ib Trial of Tecentriq + Abraxane in Patients with mTNBC (Genetech, NCT01633970) 312

Table 109: Tecentriq SWOT Analysis, 2016 312

Table 110: Product Profile-Keytruda (Pembrolizumab) 314

Table 111: Summary of the Results of Keytruda in HER2-/HR+ Patients in the KEYNOTE-028 Trial (MSD, NCT02054806) 316

Table 112: Summary of AEs of All Grades for Keytruda in HER2-/HR+ Patients in the Keytruda KEYNOTE-028 Trial (MSD, NCT02054806) 317

Table 113: Summary of Grade 3-4 AEs from the Trial of Keytruda (MSD, NCT02054806) 317

Table 114: Keytruda SWOT Analysis, 2016 318

Table 115: Product Profile-Entinostat 321

Table 116: Efficacy Results from the ENCORE301 Trial of Exemestane + Entinostat vs. Exemestane + Placebo 323

Table 117: Most Commonly Reported AEs from the ENCORE301 trial of Exemestane + Entinostat vs. Exemestane + Placebo 324

Table 118: Entinostat SWOT, 2016 326

Table 119: Product Profile-Epidaza 327

Table 120: Most Commonly Reported AEs from the Phase II Trial of Epidaza + Exemestane 330

Table 121: Epidaza SWOT Analysis 332

Table 122: Product Profile-Sacituzumab Govitecan 334

Table 123: Summary of the Results of Sacituzimab Govitecan Phase I/II Trial in Metastatic TNBC (Immunomedics Inc., NCT01631552) 336

Table 124: Summary of AEs from the Phase I/II Trial of Sacituzimab Govitecan (Immunomedics Inc., NCT01631552) 337

Table 125: Sacituzimab Govitecan SWOT, 2016 339

Table 126: Product Profile-Glembatumumab vedotin 340

Table 127: Efficacy Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Metastatic TNBC (NCT01156753) 342

Table 128: Safety Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Solid Tumors 343

Table 129: Glembatumumab Vedotin SWOT, 2016 345

Table 130: Product Profile-Xtandi 347

Table 131: Summary of the Results of ENZA Phase II Xtandi Trial (NCT01889238) 350

Table 132: Summary of the Results of Xtandi Trial 351

Table 133: Xtandi SWOT Analysis, 2016 353

Table 134: Early Stage Clinical Development in HER2- Breast Cancer 355

Table 135: Key Companies in the Disease HER2- Breast Cancer Market in the 8MM, 2015 364

Table 136: Pfizer�s HER2- Metastatic Breast Cancer Portfolio Assessment, 2016 372

Table 137: Novartis� HER2- Metastatic Breast Cancer Portfolio Assessment, 2016 374

Table 138: Roche�s HER2- Breast Cancer Portfolio Assessment, 2016 377

Table 139: AZ�s HER2- Breast Cancer Portfolio Assessment, 2016 381

Table 140: Global HER2- Breast Cancer Market-Drivers and Barriers, 2015-2025 388

Table 141: Key Events Impacting Sales for HER2-/HR+ in the US, 2015-2025 395

Table 142: Key Events Impacting Sales for TNBC in the US, 2015-2025 396

Table 143: US HER2- Breast Cancer Market-Drivers and Barriers, 2015-2025 397

Table 144: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in the 5EU, 2015-2025 403

Table 145: Key Events Impacting Sales for TNBC in the 5EU, 2015-2025 404

Table 146: 5EU HER2- Breast Cancer Market-Drivers and Barriers, 2015-2025 405

Table 147: Key Events Impacting Sales for HER2-/HR+ breast cancer in Japan, 2015-2025 411

Table 148: Key Events Impacting Sales for TNBC in Japan, 2015-2025 412

Table 149: Japanese HER2- Breast Cancer Market-Drivers and Barriers, 2015-2025 412

Table 150: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in China, 2015-2025 417

Table 151: Key Events Impacting Sales for TNBC in China, 2015-2025 418

Table 152: Chinese HER2- Breast Cancer Market-Drivers and Barriers, 2015-2025 418

Table 153: Key Launch Dates in HER2- Breast Cancer 482

Table 154: Key Patent Expiries 483

Table 155: Average Body Weight and Surface Area Across the 8MM 485

Table 156: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 505

To know more information on Purchase by Section, please send a mail to

Companies

Pfizer, Novartis, Roche, AstraZeneca

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.